Logos Global Management LP Rain Therapeutics Inc. Transaction History

Logos Global Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $296,568 - $746,118	-134,194 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$5.07 - $13.68 $562,602 - $1.52 Million	-110,967 Reduced 45.26%	134,194 $680,000
Q4 2021 Feb 14, 2022	SELL	$11.91 - $17.0 $2.62 Million - $3.74 Million	-220,170 Reduced 47.31%	245,161 $3.16 Million
Q3 2021 Nov 15, 2021	SELL	$13.21 - $20.91 $4.16 Million - $6.59 Million	-315,000 Reduced 40.37%	465,331 $6.61 Million
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $11.8 Million - $15.8 Million	780,331 New	780,331 $12.1 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Logos Global Management LP, based on Form 13F filings with the SEC.

Stay updated on Logos Global Management LP with notifications on news.